MBA Advisors LLC Reduces Stake in Johnson & Johnson (NYSE:JNJ)

MBA Advisors LLC lowered its stake in Johnson & Johnson (NYSE:JNJ) by 7.5% in the 2nd quarter, HoldingsChannel reports. The fund owned 5,469 shares of the company’s stock after selling 442 shares during the period. MBA Advisors LLC’s holdings in Johnson & Johnson were worth $799,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Innealta Capital LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $27,000. Christopher J. Hasenberg Inc purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $31,000. MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $43,000. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $44,000. Finally, Grayhawk Investment Strategies Inc. boosted its position in shares of Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Morgan Stanley boosted their target price on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. TD Cowen decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, August 5th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Stock Up 1.0 %

NYSE:JNJ traded up $1.63 during trading hours on Friday, reaching $165.86. The company’s stock had a trading volume of 7,971,017 shares, compared to its average volume of 7,271,470. The company has a market capitalization of $399.17 billion, a P/E ratio of 10.34, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $165.98. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a 50 day moving average price of $155.34 and a two-hundred day moving average price of $153.45.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.80 earnings per share. Equities analysts predict that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.